Stockscreener 앱 받기
0.3028
2.23%
0.0066
시간 외 거래:
.31
0.0072
+2.38%
Heron Therapeutics Inc 주식(HRTX)의 최신 뉴스
Heron Therapeutics Inc Estimates – BX:AXD2 - TradingView
Form 4 Heron Therapeutics Inc: Craig A. Collard (Director, CEO) For: 19 October - Investing.com Nigeria
Quarterly stock vesting gives Heron Therapeutics (HRTX) development chief 3,874 shares. - Stock Titan
Stock awards convert into 13,797 shares for Heron Therapeutics (HRTX) CEO Craig A. Collard. - Stock Titan
Heron Therapeutics: Acute Care Growth Offset by Oncology Weakness and Financial Uncertainty - Kalkine
Heron Therapeutics, Inc. (HRTX)What Are Investment Firms Thinking About This Stock? - MarketBeat
Heron Therapeutics stock at EUR 0.34 as Nasdaq move reaches 4.4 percent - ad-hoc-news.de
Investors Buy High Volume of Put Options on Heron Therapeutics (NASDAQ:HRTX) - MarketBeat
Heron Therapeutics stock gained 15.86 percent to USD 0.38 - AD HOC NEWS
Heron Therapeutics Q3 2026 Earnings Date and Estimates - MarketBeat
Heron Therapeutics stock faces a guidance reset after Q2 loss - AD HOC NEWS
Heron Therapeutics Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Highlights Recent Corporate Updates - Lelezard
Heron Therapeutics stock fell 2.33 percent on October 2 - AD HOC NEWS
Form 8K Heron Therapeutics Inc For: 29 September By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove By Investing.com - Investing.com Nigeria
Heron Therapeutics signs multi-product license agreement with Long Grove - Investing.com
Heron Therapeutics, Inc. (NASDAQ:HRTX) Stock Has Consensus Target Price of $2.00 - MarketBeat
Heron Therapeutics, Inc. (HRTX) Options Chain - finance.yahoo.com
Heron Therapeutics stock awaits its next reported figures - AD HOC NEWS
Heron Therapeutics (AXD2) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Heron Therapeutics Sees Unusually High Options Volume (NASDAQ:HRTX) - MarketBeat
HRTX - Finviz
10,550,750 Shares in Heron Therapeutics, Inc. $HRTX Bought by BlackRock Inc. - marketbeat.com
Heron Therapeutics stock trades at penny level as biotech focuses on pain and oncology pipeline - ad-hoc-news.de
AXD2 Forecast — Price Target — Prediction for 2027 - TradingView
Heron Therapeutics, Inc. (NASDAQ:HRTX) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
Heron Therapeutics Stock Short Interest Rises to 31.36% - Quiver Quantitative
Tejara Capital Ltd Buys New Stake in Heron Therapeutics, Inc. $HRTX - MarketBeat
Heron (HRTX) Results Review: EPS Comes in Below Forecast on the Day; Price Reaction: Shares Move 4.13% Down in Latest TradingEarnings Turnaround - vinanet.vn
Heron Therapeutics Earnings Call: Growth Meets New Risks - TipRanks
Heron (HRTX) Watch: Records a 4.65% Increase to $0.31 at the Close; Key Range: the Session Ends Within the Reported Technical Boundaries in the Available RecordIV Contraction - vinanet.vn
H.C. Wainwright Maintains Heron Therapeutics(HRTX.US) With Hold Rating - Moomoo
Weekly Recap: Guidance withdrawn over CINVANTI patent and HRTX Q2 revenue $37.7M - TradingView
HC Wainwright Has Pessimistic Outlook of HRTX Q3 Earnings - MarketBeat
HERON THERAPEUTICS INC : H.C. WAINWRIGHT CUTS TO NEUTRAL FROM BUY - webull.com
H.C. Wainwright Downgrades Heron Therapeutics(HRTX.US) to Hold Rating - Moomoo
--HC Wainwright Downgrades Heron Therapeutics to Neutral From Buy - Yahoo Finance
Heron Therapeutics (NasdaqCM:HRTX) Stock Forecast & Analyst Predictions - Simply Wall Street
Heron Therapeutics earnings missed by $0.02, revenue fell short of estimates - Investing.com Canada
Heron Therapeutics Inc (HRTX) (Q2 2026) Earnings Call Highlights: Revenue Growth Amid Strategic ... - finance.yahoo.com
Heron Therapeutics Q2 2026 Loss Widens 50.0% Beyond Estimates - AlphaStreet
Heron Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Heron Therapeutics Q2 2026 Earnings Call Transcript - MarketBeat
Heron Therapeutics Withdraws 2026 Guidance as CINVANTI Patent Risk and Strategic Review Cloud Outlook - Yahoo Finance
Earnings call transcript: Heron Therapeutics misses Q2 2026 revenue forecast By Investing.com - Investing.com Canada
Heron Therapeutics Q2 Earnings Call Highlights - MarketBeat
Heron Therapeutics Q2 Earnings Call Highlights - Yahoo Finance
Heron Therapeutics (HRTX) Reports Q2 Loss, Lags Revenue Estimates - finance.yahoo.com
development in the article - Minichart
Heron Therapeutics (NASDAQ:HRTX) Issues Earnings Results - MarketBeat
3.09%
0.72%
자본화:
|
볼륨(24시간):